GlassScriptPhysician profile
Rochelle E Ablah
NPI 1366656647
$2,177.34
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $438 · 2021: $339 · 2022: $428 · 2023: $484 · 2024: $29.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $292.99 | 2021-2024 | |
| Janssen Biotech, INC. | $148.26 | 2020-2023 | |
| Genentech USA, INC. | $113.12 | 2019 | |
| Lilly USA, LLC | $109.69 | 2021-2023 | Retevmo, Jaypirca, Verzenio |
| Pharmacyclics LLC, An Abbvie Company | $94.39 | 2019-2023 | Imbruvica, Epkinly |
| Amgen INC. | $70.15 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $69.07 | 2022-2023 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $63.56 | 2022-2023 | Ninlaro, Iclusig |
| Incyte Corporation | $62.53 | 2020-2023 | Jakafi |
| Astrazeneca Pharmaceuticals LP | $50.68 | 2019-2020 | |
| Servier Pharmaceuticals LLC | $46.54 | 2022 | |
| Eisai INC. | $35.15 | 2019-2022 | |
| Tersera Therapeutics LLC | $34.29 | 2020-2021 | |
| Abbvie INC. | $31.41 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $31.28 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.21 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.78 | 2023 | |
| Advanced Accelerator Applications | $18.73 | 2020 | |
| Sun Pharmaceutical Industries INC. | $18.45 | 2022 | |
| Karyopharm Therapeutics INC. | $14.33 | 2021 | |
| Genmab U.S., INC. | $12.80 | 2022 | |
| Novocure INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rochelle Ablah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.